Accelalox Inc Profile last edited on: 9/28/2016
CAGE: 5BJ11
UEI: T4EKFBZGN975
Business Identifier: Oral and small-molecule therapies to treat muscle and bone conditions 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
325 Sharon Park Drive Suite 310
Menlo Park, CA 94025
Menlo Park, CA 94025
| (650) 854-1465 |
| forinfo@accelalox.com |
| www.accelalox.com |
Location: Single
Congr. District: 18
County: San Mateo
Congr. District: 18
County: San Mateo
Public Profile
Accelalox Inc. is developing therapies to treat musculoskeletal conditions. Initial development program ifocused on an oral, small-molecule therapy to significantly accelerate and enhance bone healing. This therapy will be used for bone fractures and spinal fusions to improve patient outcomes through accelerated healing and reduced complications
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2010 | 1 | NIH | $228,827 | |
| Project Title: Pharmacological Method To Accelerate Bone Fracture Healing | ||||
Key People / Management
Julia A O�Connor -- Chief Executive Officer and Founder
J Patrick O'Connor -- Chief Scientific Officer and Founder
J Patrick O'Connor -- Chief Scientific Officer and Founder
Company News
There are no news available.
